Q3 Earnings Forecast for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for CorMedix in a report released on Tuesday, May 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of $0.13 per share for the quarter, down from their prior forecast of $0.16. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s FY2025 earnings at $0.68 EPS.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.05. The firm had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million. During the same quarter in the previous year, the business earned ($0.25) EPS.

Several other research analysts have also recently commented on CRMD. Royal Bank of Canada reaffirmed an “outperform” rating and set a $12.00 target price on shares of CorMedix in a report on Wednesday, March 26th. Leerink Partners began coverage on CorMedix in a research note on Friday, March 7th. They set an “outperform” rating and a $18.00 price objective on the stock. Needham & Company LLC lifted their price objective on CorMedix from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of CorMedix in a report on Tuesday. Finally, StockNews.com raised CorMedix from a “sell” rating to a “hold” rating in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CorMedix presently has a consensus rating of “Buy” and an average price target of $15.00.

CorMedix Stock Performance

NASDAQ:CRMD opened at $11.66 on Thursday. CorMedix has a 52 week low of $3.61 and a 52 week high of $13.85. The firm’s 50-day simple moving average is $8.73 and its 200 day simple moving average is $9.77. The firm has a market cap of $790.66 million, a price-to-earnings ratio of -14.39 and a beta of 1.54.

Institutional Trading of CorMedix

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its position in CorMedix by 1.9% in the fourth quarter. Bank of America Corp DE now owns 60,115 shares of the company’s stock valued at $487,000 after purchasing an additional 1,124 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in CorMedix by 1.0% in the fourth quarter. Nuveen Asset Management LLC now owns 171,978 shares of the company’s stock valued at $1,393,000 after buying an additional 1,679 shares during the period. AlphaMark Advisors LLC boosted its position in shares of CorMedix by 16.7% during the 4th quarter. AlphaMark Advisors LLC now owns 14,000 shares of the company’s stock valued at $113,000 after purchasing an additional 2,000 shares in the last quarter. Sigma Planning Corp increased its stake in shares of CorMedix by 7.8% in the 1st quarter. Sigma Planning Corp now owns 36,305 shares of the company’s stock valued at $224,000 after acquiring an additional 2,612 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of CorMedix by 1.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 177,188 shares of the company’s stock worth $1,091,000 after purchasing an additional 2,770 shares in the last quarter. 34.18% of the stock is currently owned by institutional investors.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.